Skip to main content
FDA Shortage Check

Is Xylocaine (Epinephrine Bitartrate, Lidocaine Hydrochloride Injection) in shortage?

Label: plusbeauxjours · shortage label · not a prescription, not a pharmacy, not FDA

IN SHORTAGE

Xylocaine: in shortage (FDA, Oct 24)

Injections (vials)
A generic injection, not your medicine. We draw dosage forms, not products, and never pills you could match to yours.
  • Reason: “Demand increase for the drug”. FDA shortage reason (FDASIA), reported by the manufacturer
  • Reason: “Other”. FDA shortage reason (FDASIA), reported by the manufacturer
  • Estimate: “Estimated Recovery: June 2027”. Manufacturer’s estimate, Hospira, Inc., a Pfizer Company, Oct 21, 2026
DRUG
Xylocaine
FDA LISTING
FORM
injection
STATUS
Currently in Shortage
FIRST POSTED
Feb 22, 2012
LAST FDA UPDATE
Oct 21, 2026
AS OF
Oct 24, 2026
SOURCE

FDA lists 22 presentations: 7 unavailable · 6 limited · 9 available.

FDA Drug Shortages checked Oct 24, 2026, 21:05 ET · FDA updates daily · manufacturer-reported

Information from FDA’s drug shortage list, reported by manufacturers. Not medical advice. Don’t stop, change or ration a medicine without talking to your prescriber or pharmacist.

FDA's listing, word for word: Epinephrine Bitartrate, Lidocaine Hydrochloride Injection. 22 presentations from 2 makers.

Check your own medication, form and strength

What to ask at the counter

  1. Is this a supply problem at this pharmacy, or everywhere? Could another pharmacy have it? FDA consumer FAQ (opens in a new tab)
  2. Is my strength or the maker you stock affected? FDA list, by presentation
  3. Is there an alternative to this medicine I should ask my prescriber about? FDA consumer FAQ (opens in a new tab)
  4. When should I check back, or can you order it?

FDA: “talk with your health care provider or pharmacist for other treatment options during the shortage.” FDA Drug Shortages page (opens in a new tab)

This listing on FDA ↗ (opens in a new tab)Report a shortage to FDA: drugshortages@fda.hhs.gov

Every presentation FDA lists, by maker

Availability is FDA's text for each package, as the manufacturer reported it. Makers with unavailable or limited packages come first.

Fresenius Kabi USA, LLC12 presentations · 3 unavailable · 9 available or not stated

Contact (FDA's listing): 888-386-1300

  • .005 mg/1 mL; 20 mg/1 mL

    Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)

    Next release October 2026. Check wholesalers for inventory.

    NDC 63323-489-27Reverified

    Unavailable

  • .005 mg/1 mL; 5 mg/1 mL

    Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)

    Next release October 2026. Check wholesalers for inventory.

    NDC 63323-481-57Reverified

    Unavailable

  • .01 mg/1 mL; 10 mg/1 mL

    Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)

    Next release November 2026. Check wholesalers for inventory.

    NDC 63323-482-17Reverified

    Unavailable

  • .005 mg/1 mL; 10 mg/1 mL

    Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)

    Check wholesalers for inventory

    NDC 63323-487-17Reverified

    Available

  • .005 mg/1 mL; 10 mg/1 mL

    Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)

    Check wholesalers for inventory

    NDC 63323-487-37Reverified

    Available

  • .005 mg/1 mL; 15 mg/1 mL

    Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)

    Check wholesalers for inventory

    NDC 63323-488-17Reverified

    Available

  • .005 mg/1 mL; 15 mg/1 mL

    Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)

    Check wholesalers for inventory

    NDC 63323-488-37Reverified

    Available

  • .005 mg/1 mL; 20 mg/1 mL

    Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)

    Check wholesalers for inventory

    NDC 63323-489-17Reverified

    Available

  • .01 mg/1 mL; 10 mg/1 mL

    Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)

    Check wholesalers for inventory

    NDC 63323-482-27Reverified

    Available

  • .01 mg/1 mL; 10 mg/1 mL

    Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)

    Check wholesalers for inventory

    NDC 63323-482-57Reverified

    Available

  • .01 mg/1 mL; 20 mg/1 mL

    Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)

    Check wholesalers for inventory

    NDC 63323-483-27Reverified

    Available

  • .01 mg/1 mL; 20 mg/1 mL

    Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)

    Check wholesalers for inventory

    NDC 63323-483-57Reverified

    Available

Hospira, Inc., a Pfizer Company10 presentations · 4 unavailable · 6 limited

Contact (FDA's listing): 844-646-4398

  • 250 mg/50 mL (0.5%; 1:200,000)

    Lidocaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)

    Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay

    NDC 0409-3177-01Revised

    Unavailable

  • 300 mg/30 mL (1%; 1:100,000)

    Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)

    Next Delivery: January 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay

    NDC 0409-3178-02Revised

    Unavailable

  • 400 mg/20 mL (2%; 1:100,000)

    Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)

    Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay

    NDC 0409-3182-01Revised

    Unavailable

  • 75 mg/5 mL (1.5%; 1:200,000)

    Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)

    Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay

    NDC 0409-1209-01Revised

    Unavailable

  • 1 g/50 mL (2%; 1:100,000)

    Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)

    Limited Supply Available. Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay

    NDC 0409-3182-03Revised

    Limited Availability

  • 200 mg/20 mL (1%; 1:100,000)

    Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)

    Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay

    NDC 0409-3178-01Revised

    Limited Availability

  • 400 mg/20 mL (2%; 1:200,000)

    Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)

    Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay

    NDC 0409-3183-01Revised

    Limited Availability

  • 450 mg/30 mL (1.5%; 1:200,000)

    Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)

    Limited Supply Available. Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay

    NDC 0409-3181-01Revised

    Limited Availalbility

  • 500 mg/50 mL (1%; 1:100,000)

    Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)

    Limited Supply Available. Next Delivery: April 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay

    NDC 0409-3178-03Revised

    Limited Availability

  • 600 mg/30 mL (2%; 1:100,000)

    Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)

    Limited Supply Available. Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay

    NDC 0409-3182-02Revised

    Limited Availability

What the manufacturers told FDA

  • Fresenius Kabi USA, LLC · ‘Next release November 2026. Check wholesalers for inventory.’ · updated Oct 2026
  • Fresenius Kabi USA, LLC · ‘Next release October 2026. Check wholesalers for inventory.’ · updated Oct 2026
  • Hospira, Inc., a Pfizer Company · ‘Limited Supply Available. Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay’ · updated Oct 2026
  • Hospira, Inc., a Pfizer Company · ‘Limited Supply Available. Next Delivery: April 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay’ · updated Oct 2026
  • Hospira, Inc., a Pfizer Company · ‘Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay’ · updated Oct 2026

More on FDA ↗ (opens in a new tab)

Reason for the shortage (FDASIA)

  • Demand increase for the drug
  • Other

As reported by the manufacturer under the Food and Drug Administration Safety and Innovation Act.

Alternatives

FDA lists none: “Providing a list of alternative drug products for a drug in shortage is part of the ‘practice of medicine.’ FDA does not regulate the practice of medicine.” Your prescriber or pharmacist can talk through options with you. ASHP also tracks shortages and suggested alternatives (different criteria) ↗ (opens in a new tab)

Questions

Is Xylocaine in shortage?
Yes. As of Oct 24, 2026, FDA lists Epinephrine Bitartrate, Lidocaine Hydrochloride Injection as currently in shortage: 22 presentations, 7 unavailable and 6 limited.
When will the Xylocaine shortage end?
FDA gives no end date. 10 presentations carry a manufacturer’s own estimate, quoted on this page with its date.
Does FDA list alternatives to Xylocaine?
No. FDA calls a list of alternatives part of the ‘practice of medicine’. Ask your pharmacist or prescriber.